Dark
Streaming/Mobile
OldĀ Site
Home
Products
Help
Contact Us
Your Account
System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:47:34 EDT Sun 28 Apr 2024
Quotes
Streaming/Mobile
Quick Quotes (x20)
Symbol Search
Company Search
Market Depth
US Options
Montreal Options
Foreign Exchange
Download Close Prices
Short History
Quotes Help
Charts
12 Month Chart
Advanced Chart
Live Intraday Chart
Live Historical Chart
Live Java Intraday Chart
Live Java Historical Chart
Charts Help
News
News Search
SEDAR Search
SEDAR Alerts
News Help
Indexes
Major Indexes
US incl Dow Jones
NASDAQ
S&P CME
PBOT - Phil Ex
TSX - Toronto
TSX-V - TSX Venture
Indexes Help
Portfolio
View Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Value Portfolio
All Portfolios
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Edit Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Chart Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Live Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
View Portfolio News
Daily Summary
Portfolio Help
Analytics
Exchange Statistics
Most Active
Live Most Active
Block Trades
Broker Trades
Halted Stocks
Dividends
Participants
Companies
Trade Workstation
Company Picker
Short Positions
Broker Codes
Analytics Help
Mutual Funds
Mutual Fund Search
Targeted Holder Search
SEDAR Fund Search
Mutual Fund Help
Enter Symbol
or Name
USA
CA
Quote
Chart
News
Closes
Depth
Forgot password?
Trouble logging in?
Login to Stockwatch
News for U:SEEL from 2023-04-27 to 2024-04-26 - 20 items
News Releases
In The News
Other
CA
US
Date
Sym
Price
Type
Headline
2024-03-19 08:15
U
U:SEEL
News Release
200
Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)
2024-01-26 08:30
U
U:SEEL
News Release
200
Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
2024-01-22 08:00
U
U:SEEL
News Release
200
Seelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration (FDA) Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002
2024-01-02 08:00
U
U:SEEL
News Release
200
Leading Independent Proxy Advisory Firm ISS Recommends Seelos Stockholders Vote "FOR" All Proxy Proposals at the Special Meeting to be held on January 10, 2024
2023-12-22 08:00
U
U:SEEL
News Release
200
Seelos Therapeutics, Inc. Releases Letter to its Stockholders
2023-12-01 16:00
U
U:SEEL
News Release
200
Seelos Therapeutics Announces Closing of Public Offering
2023-11-28 21:26
U
U:SEEL
News Release
200
Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering
2023-11-28 16:06
U
U:SEEL
News Release
200
Seelos Therapeutics Announces Proposed Public Offering
2023-11-27 08:00
U
U:SEEL
News Release
200
Seelos Therapeutics Announces the Selection of SLS-002 (intranasal racemic ketamine) for Inclusion in the U.S. Department of Defense's Adaptive Platform Trial to Evaluate Potential Treatments for Post-Traumatic Stress Disorder (PTSD)
2023-11-24 10:53
U
U:SEEL
News Release
200
Seelos Therapeutics Announces 1-for-30 Reverse Stock Split
2023-10-27 08:11
U
U:SEEL
News Release
200
Seelos Therapeutics to Present a Poster on SLS-005 in Alzheimer's Disease at Neuroscience 2023
2023-10-17 08:00
U
U:SEEL
News Release
200
Seelos Therapeutics Retains Canaccord Genuity in Connection with Review of Potential Partnerships and Collaborations
2023-09-27 08:00
U
U:SEEL
News Release
200
Seelos Therapeutics Announces Encouraging Data from an In Vivo Study of SLS-005 in an Aggressive Preclinical Model of Alzheimer's Disease
2023-09-21 09:00
U
U:SEEL
News Release
200
Seelos Therapeutics Announces Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock
2023-09-20 07:00
U
U:SEEL
News Release
200
Seelos Therapeutics Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicide
2023-08-14 08:00
U
U:SEEL
News Release
200
Seelos Therapeutics Provides Second Quarter 2023 Clinical Update
2023-06-22 08:00
U
U:SEEL
News Release
200
Seelos Therapeutics Announces the Close of Enrollment of its Registration Directed Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior (ASIB) in Adults with Major Depressive Disorder (MDD)
2023-05-22 08:00
U
U:SEEL
News Release
200
Seelos Therapeutics to Participate in Two Upcoming Healthcare Conferences
2023-05-15 08:00
U
U:SEEL
News Release
200
Seelos Therapeutics Provides Clinical Update and Reports First Quarter 2023 Financial Results
2023-05-05 08:00
U
U:SEEL
News Release
200
Seelos Therapeutics to Present a Poster on SLS-009 at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting